...
首页> 外文期刊>Clinical Science >Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria
【24h】

Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria

机译:基质金属蛋白酶9在慢性肾脏疾病中的作用:耐药蛋白尿的新生物标志物

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Resistant albuminuria, developed under adequate chronic blockade of the renin-angiotensin system, is a clinical problem present in a small number of patients with chronic kidney disease (CKD). The mechanism underlying this resistant albuminuria remains unknown. Matrix metalloproteinases (MMPs) are involved in the pathophysiology of cardiovascular and renal diseases. In the present study we tested the role of MMPs in resistant albuminuria. First we evaluated gelatinase MMP-2 and MMP-9 activity by zymography in the Munich Wistar Fromter (MWF) rat, a model of progressive albuminuria, and subsequently in patients with resistant albuminuria. Markers of oxidative stress were observed in the kidneys of MWF rats, together with a significant increase in pro-MMP-2 and active MMP-9 forms. These changes were normalized together with reduced albuminuria in consomic MWF-8(SHR) rats, in which chromosome 8 of MWF was replaced with the respective chromosome from spontaneously hypertensive rats. The MMP-2 and MMP-9 protein levels were similar in patients with normal and resistant albuminuria; however, high circulating levels of collagen IV, a specific biomarker of tissue collagen IV degradation, were observed in patients with resistant albuminuria. These patients showed a significant increase in gelatinase MMP-2 and MMP-9 activity, but only a significant increase in the active MMP-9 form quantified by ELISA, which correlated significantly with the degree of albuminuria. Although the expression of the tissue inhibitor of MMP-9 (TIMP)-1 was similar, a novel AlphaLISA assay demonstrated that the MMP-9-TIMP-1 interaction was reduced in patients with resistant albuminuria. It is of interest that oxidized TIMP-1 expression was higher in patients with resistant albuminuria. Therefore, increased circulating MMP-9 activity is associated with resistant albuminuria and a deleterious oxidative stress environment appears to be the underlying mechanism. These changes might contribute to the progression of CKD in these patients.
机译:在肾素-血管紧张素系统的充分慢性阻滞下发展的耐药性白蛋白尿是少数慢性肾脏病(CKD)患者的临床问题。这种抗性蛋白尿的机制尚不清楚。基质金属蛋白酶(MMPs)参与心血管和肾脏疾病的病理生理。在本研究中,我们测试了MMP在抗性蛋白尿中的作用。首先,我们通过酶谱法评估了进行性白蛋白尿的模型-慕尼黑Wistar Fromter(MWF)大鼠的明胶酶MMP-2和MMP-9的活性,随后对耐药白蛋白尿的患者进行了评估。在MWF大鼠的肾脏中观察到氧化应激的标志物,pro-MMP-2和活性MMP-9形式显着增加。将这些变化与减少的蛋白尿在正常的MWF-8(SHR)大鼠中归一化,其中将MWF的8号染色体替换为自发性高血压大鼠的相应染色体。蛋白尿正常和耐药的患者的MMP-2和MMP-9蛋白水平相似。然而,在抵抗性白蛋白尿患者中观察到了高循环水平的胶原蛋白IV,这是组织胶原蛋白IV降解的特定生物标记。这些患者显示明胶酶MMP-2和MMP-9活性显着增加,但通过ELISA定量的活性MMP-9形式仅显着增加,这与蛋白尿程度显着相关。尽管MMP-9(TIMP)-1的组织抑制剂的表达相似,但新的AlphaLISA分析表明,耐药性蛋白尿患者MMP-9-TIMP-1的相互作用降低。有趣的是,抗性白蛋白尿患者的氧化TIMP-1表达更高。因此,增加的循环MMP-9活性与抗性蛋白尿有关,有害的氧化应激环境似乎是其潜在机制。这些改变可能有助于这些患者CKD的进展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号